Medtronic PLC $MDT Shares Sold by Capitolis Liquid Global Markets LLC

Capitolis Liquid Global Markets LLC cut its holdings in shares of Medtronic PLC (NYSE:MDT) by 71.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 310,000 shares of the medical technology company’s stock after selling 764,200 shares during the period. Capitolis Liquid Global Markets LLC’s holdings in Medtronic were worth $29,524,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Ausdal Financial Partners Inc. acquired a new stake in Medtronic during the 3rd quarter worth approximately $391,000. California Public Employees Retirement System grew its stake in shares of Medtronic by 57.9% in the third quarter. California Public Employees Retirement System now owns 5,101,347 shares of the medical technology company’s stock worth $485,852,000 after acquiring an additional 1,870,495 shares in the last quarter. Chilton Investment Co. Inc. increased its position in shares of Medtronic by 4.4% during the third quarter. Chilton Investment Co. Inc. now owns 208,283 shares of the medical technology company’s stock worth $19,837,000 after acquiring an additional 8,790 shares during the period. Boothbay Fund Management LLC increased its position in shares of Medtronic by 14.2% during the third quarter. Boothbay Fund Management LLC now owns 2,694 shares of the medical technology company’s stock worth $257,000 after acquiring an additional 335 shares during the period. Finally, Alliancebernstein L.P. raised its stake in shares of Medtronic by 41.8% in the third quarter. Alliancebernstein L.P. now owns 7,921,480 shares of the medical technology company’s stock valued at $754,442,000 after acquiring an additional 2,333,686 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

Shares of MDT stock opened at $87.05 on Friday. The company has a market cap of $111.77 billion, a P/E ratio of 24.25, a PEG ratio of 2.23 and a beta of 0.71. The firm has a fifty day moving average price of $97.96 and a 200 day moving average price of $96.87. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12 month low of $79.55 and a 12 month high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.Medtronic’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Insiders Place Their Bets

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

MDT has been the subject of a number of recent research reports. Jefferies Financial Group reiterated a “hold” rating and issued a $110.00 target price on shares of Medtronic in a report on Wednesday, November 19th. Sanford C. Bernstein increased their price target on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. Truist Financial decreased their price objective on Medtronic from $107.00 to $103.00 and set a “hold” rating for the company in a research note on Wednesday, February 18th. Needham & Company LLC reiterated a “buy” rating and issued a $120.00 price objective on shares of Medtronic in a research note on Tuesday. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $110.74.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).